F‐18 <scp>FDG PET</scp>/<scp>CT</scp> quantization parameters as predictors of outcome in patients with diffuse large <scp>B</scp>‐cell lymphoma

Abstract

Despite the availability of new tools for the quantitative assessment of disease activity on PET/CT, the SUVmax rather than MTV and TLG remains the only predictor for EFS in DLBCL patients. The magnitude of glycolytic activity rather than the amount of metabolically active burden holds a predominant value for determining the response to chemotherapy in DLBCL.